CrossBridge Bio, Inc. Receives $2.6M in Non-Dilutive Funding from CPRIT to Advance, CBB-120, a Next-Generation Dual-Payload Antibody-Drug Conjugate for the Treatment of TROP-2+ Solid Tumors 

CrossBridge Bio, Inc. proudly announces the receipt of a substantial competitive non-dilutive grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This grant marks a significant milestone in CrossBridge's mission to propel its innovative dual-payload ADC platform and potential best-in-class TROP2 program, CBB-120, to IND-enabling studies.